Generate Biomedicines (GENB) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.23 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | OCUL |
|---|---|---|
| Share price | $9.54 | $5.57 |
| Market cap | $1.23B | $1.23B |
| 1-day change | -8.00% | -4.95% |
| YTD return | — | -54.12% |
| 1-year return | — | -54.49% |
| 5-year return | — | -14.83% |
| EPS (TTM) | $-2.49 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | — | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $22.67 | $16.44 |
| 52-week low | $9.40 | $5.54 |
| Distance from 52-week high | -57.92% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +183.02% | +361.94% |
| Average volume | 1.24M | 3.03M |
| Shares outstanding | 129.10M | 220.02M |
| Employees | 312 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
GENB vs OCUL FAQ
Which is bigger, Generate Biomedicines or Ocular Therapeutix?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.23B for Ocular Therapeutix (OCUL).
Are Generate Biomedicines and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.